Intervention Review

Betamimetics for suspected impaired fetal growth

  1. Lale Say1,*,
  2. A Metin Gülmezoglu2,
  3. G Justus Hofmeyr3

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 23 JUN 2009

DOI: 10.1002/14651858.CD000036

Database Title

Additional Information

How to Cite

Say L, Gülmezoglu AM, Hofmeyr GJ. Betamimetics for suspected impaired fetal growth. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD000036. DOI: 10.1002/14651858.CD000036.

Author Information

  1. 1

    World Health Organization, Department of Reproductive Health and Research, Geneva, Switzerland

  2. 2

    World Health Organization, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, Geneva, Switzerland

  3. 3

    University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health, Department of Obstetrics and Gynaecology, East London Hospital Complex, East London, Eastern Cape, South Africa

*Lale Say, Department of Reproductive Health and Research, World Health Organization, 20 Avenue Appia, Geneva, 1211, Switzerland. sayl@who.int.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 7 OCT 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (56K)Standard (132K)Full (156K)
 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Background

Betamimetic drugs may promote fetal growth by increasing the availability of nutrients and by decreasing vascular resistance. They may also induce adverse effects via their effects on carbohydrate metabolism.

Objectives

The objective of this review was to assess the effects of betamimetic therapy for suspected impaired fetal growth on fetal growth and perinatal outcome.

Search methods

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2009).

Selection criteria

Randomized trials of betamimetic therapy compared with no betamimetic therapy or placebo in women with suspected impaired fetal growth.

Data collection and analysis

Eligibility and trial quality was assessed.

Main results

Two studies of 118 women were included. No statistically significant differences were found between the betamimetic groups and the control groups for low birthweight (risk ratio 1.17, 95% confidence interval 0.75 to 1.83), other anthropometric measures or neonatal morbidity and mortality.

Authors' conclusions

Larger, well-designed studies are needed to evaluate the effects of betamimetics on fetal growth. Since there is potential for adverse effects due to the pharmacological characteristics of this group of drugs, data related to any potential harms should be collected in addition to beneficial effects.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Betamimetics for suspected impaired fetal growth

Too little evidence to show whether betamimetic drugs for women during pregnancy benefits unborn babies who are smaller than expected.

Betamimetic drugs such as ritodrine relax muscles and help the body break down sugar found in fruit and meat (glucose) for energy. It has been thought that betamimetic drugs taken by mouth or injection by women who are more than 27 weeks' pregnant may improve the growth of unborn babies who are smaller than expected (impaired fetal growth). The review of two trials (118 women) has found too little evidence to show whether the unborn baby's growth improves when the mother takes betamimetic drugs. More research is needed into the short and long-term effects of betamimetic drugs on women and their babies.

 

摘要

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

背景

Betamimetics類藥物用於疑似發育不佳之胎兒

Betamimetic類藥物可以藉由增加營養和減少血管阻力而促進胎兒生長，也會因對碳水化合物代謝的效果誘發副作用

目標

目標是評估betamimetic治療用於疑似胎兒生長不佳時，對胎兒生長和生產前後結果的效果

搜尋策略

我們搜尋 Cochrane Pregnancy和Childbirth Group's Trials Register(2007年10月)

選擇標準

比較betamimetic治療、無betamimetic治療或安慰劑的隨機試驗，研究對象是疑似胎兒生長不佳的孕婦

資料收集與分析

評估適用性與試驗品質

主要結論

納入2篇研究、118名婦女。betamimetic 組和對照組之間，在低出生體重(RR為1.17, 95% CI為0.75 – 1.83)、其他人體計測或新生兒發病率和死亡率方面，沒有顯著差異

作者結論

需要較大型且設計良好的研究來評估betamimetics對胎兒生長的效果。因為這類藥物的藥理特徵而可能有副作用，除了效果資料之外，應納入與任何潛在傷害有關的資料

翻譯人

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌

總結

證據太少，無法顯示孕婦使用betamimetic類藥物，對於原本預期生長不佳的胎兒是否有幫助。Betamimeti 類藥物如ritodrine，可鬆弛肌肉與幫助身體分解水果和肉類的糖分(葡萄糖)以提供能量。一般認為，懷孕27週以上孕婦服用或注射betamimetic類藥物，可以改善原本預期生長不佳的胎兒(胎兒發育不良)生長。此次回顧發現，證據太少而無法顯示孕婦使用betamimetic類藥物是否可改善胎兒的生長。需要更多研究探討Betamimeti 類藥物對於孕婦和胎兒的短期和長期效果

View Full Article (HTML) Summary (56K)Standard (132K)Full (156K)